Drug Discovery

Lonza Enters Pluripotent Stem Cell Market through Distribution Arrangement for...

Axiogenesis claims that its Cor.At murine ESC-derived cardiomyocytes represent the first physiologically relevant disease model of cardiomyopathy.

Broadly Neutralizing Antibody Can Pin HIV with Either of Dual Holds

Structural analysis of 8ANC195, a broadly neutralizing antibody against HIV, revealed a new conformation of the virus’s signature envelope protein. The antibody is shown...

Candidate Immunotherapy Target Identified for Brain Cancer, Possibly Other Tumors

Scientists at Dana-Farber Cancer Institute, Massachusetts General Hospital, and the Broad Institute of MIT and Harvard, discovered a potential new target for malignant brain tumor immunotherapy. The results of their studies showed that the immune cell surface receptor, CD161, suppresses the cancer-fighting activity of immune T cells, and is activated by its ligand, CLEC2D, on tumor cells and immune-suppressing cells in the brain. Their studies further demonstrated how blocking this pathway increased T cell-mediated killing of glioma cells in vitro and their anti-tumor function in animal models.

Grünenthal to Buy Ex-Japan Global Rights to AstraZeneca’s Migraine Drug for...

AstraZeneca has agreed to sell worldwide (excluding Japan) rights to its migraine drug Zomig® (zolmitriptan) to Germany-based Grünenthal for $200 million upfront and potentially...

Insulin and Amylin Combined as a Potential New Therapy for Diabetes

A Stanford researcher's advance might enable patients with diabetes to take a double-acting shot that contains insulin in combination with a drug based on a second hormone, amylin, which plays a synergistic role with insulin to control blood sugar levels after eating in a way that is more effective than insulin alone and mimics what occurs naturally with a meal.

Abbott, Emergent Terminate Co-Development Deal for B-Cell Cancers

Emergent separately confirms start of Phase II study with TRU-016 in CLL patients.

Scientists Describe New Approaches to Generating Regulatory T Cells for Preventing...

Three different methods allow large-scale expansion of clinically relevant quantities of immunosuppressive T cells.

Top 10 Pharma Companies of 2019

Overall, the top 10 pharma companies on this year’s GEN list generated a combined $1.792 trillion in market cap,is down 2.9% fromGEN’s A-List of Top 10 Pharma Companies of 2018, but up 4% from the Top 10 Pharma Companies of 2017, a year in which pharma stocks recovered from the previous year’s election-related investor fears of curbs on rising prescription drug prices. If nothing else, those results confirm the age-old advice that stock investors should think long-term if they want the best results.

Engineered “Bubbles” as a Cancer Drug Delivery System

Bubbly extracellular vesicles could become mini treatment transporters, carrying a combination of therapeutic drugs and genes that target cancer cells and kill them, according to new research from Michigan State University and Stanford University.

Overcoming the Challenges of Infectious Diseases with Label-Free Approaches

In response to the global COVID-19 pandemic, vaccine research and manufacturing processes have seen unprecedented advancements over a short timeframe. This eBook, sponsored by Sartorius, explores the latest methodologies and suggests alternative strategies in the development of future vaccines to fight the huge variety of infectious diseases.